Decision made after reviewing results of interim analysis LONDON – January 7, 2026 – Pulmocide Ltd., (“the Company”), a late-stage […]
Pulmocide Announces Termination of Opera-T Phase 3 Study with Opelconazole Read More »
LONDON – January 10, 2025 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering
Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference Read More »
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference Read More »
LONDON – October 16, 2023 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients
LONDON, June 08, 2023 — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering
Pulmocide Announces Expansion of Management Team Read More »
Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole Read More »
Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients
Pulmocide Receives Investment from the Cystic Fibrosis Foundation Read More »
Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients
– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and
